Jadiza

Ethinylestradiol and Levonorgestrel, the active ingredients in Jadiza, are combined estrogen‑progestogen oral contraceptives presented as oral tablets for oral use. They work together to prevent pregnancy in women of reproductive age and comply with EU regulatory standards, requiring a prescription from a qualified health professional.

GNH USA supplies Jadiza as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable global distribution and supporting customers with technical and regulatory assistance, and ensuring compliance with local import regulations.

Jadiza, a combined estrogen‑progestogen oral contraceptive, is used to regulate hormonal pathways that prevent pregnancy.

Contraception: prevents pregnancy by inhibiting ovulation, thickening cervical mucus, and altering the endometrium. Family planning: provides a reliable, reversible method of birth control for women of reproductive age. Menstrual cycle regulation: helps achieve more predictable bleeding patterns and reduces menstrual‑related discomfort. Hormonal balance: stabilizes estrogen and progesterone levels during the menstrual cycle.

Jadiza may cause a range of adverse reactions, which are generally classified by frequency.

Common Side Effects: - Nausea - Headache - Breast tenderness - Spotting between periods

Serious or Rare Side Effects: - Deep vein thrombosis - Pulmonary embolism - Severe allergic reaction (anaphylaxis)

When prescribing Jadiza, healthcare professionals should consider several safety precautions.

Pregnancy avoidance: product is contraindicated in pregnancy (Category X). Smoking: avoid use in women over 35 who smoke due to increased thrombotic risk. Cardiovascular risk: assess history of thromboembolic disorders before initiating therapy. Liver disease: use with caution in patients with hepatic impairment. Drug review: evaluate concomitant medications that may reduce contraceptive effectiveness. Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Jadiza can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin) may markedly reduce contraceptive effectiveness. - Concurrent use with other estrogen‑containing products increases risk of estrogen‑related adverse events.

Moderate Interactions (Monitor Closely): - Antifungal agents such as ketoconazole can increase plasma levels of levonorgestrel, requiring monitoring for side effects. - St. John’s wort may lower effectiveness of hormonal contraception; consider alternative birth control. - Anticoagulants may increase the risk of thrombotic events when combined with hormonal contraceptives; monitor clotting parameters.